At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...
At the American College of Cardiology (ACC) 2026 Scientific Session, Boston Scientific presented results from two late-breaking randomized controlled trials evaluating device-based approaches in cardiovascular care: CHAMPION-AF, studying the...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care
With FDA clearance and CE marking, IntraSight Plus...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
The study found that AK-AVS can detect aortic stenosis through routine ECGs up to 4.5 years before TAVR intervention, potentially enabling earlier detection, easier-to-access monitoring, and better timing of intervention.
The study found that AK-AVS can detect aortic stenosis through routine ECGs up to 4.5 years before TAVR intervention, potentially enabling earlier detection, easier-to-access monitoring, and better timing of intervention.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Salus Scientific and Tallahassee Memorial HealthCare (TMH) announced the successful implementation and first clinical use of AeroShield™, a groundbreaking radiation protection technology developed by Salus Scientific.
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
Sunnyvale, California – Avantec Vascular, a NIPRO Company, has received FDA 510(k) clearance for a thrombectomy system that will enable a new type of treatment for patients with thrombus in the peripheral venous...
New York, NY – Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the heart and increase the risk...
New York, NY – Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the heart and increase the risk...
The HOTWIRE™ Transseptal Access System combines a novel RF guidewire with a next-generation RF generator designed to optimize transseptal access, streamline procedural workflows and improve patient outcomes with the best-in-class platform for...
The HOTWIRE™ Transseptal Access System combines a novel RF guidewire with a next-generation RF generator designed to optimize transseptal access, streamline procedural workflows and improve patient outcomes with the best-in-class platform for...
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
